Peripheral blood immunoglobulin A antibody-secreting-cell (ASC) responses are thought to reflect the mucosal immune response to locally presented antigens. We evaluated the ASC response to cholera toxin (CT) following challenge for all vaccinees. V. chokerae-specific ASC responses following antigenic reexposure gave information on the presence of mucosal B memory cells but did not correlate with protective immunity. As such, these ASC assays will have limited usefulness for evaluating vaccine responders in vaccine field trials in cholera-endemic areas where prior V. chokerae 01 exposure is unknown.
following primary immunization, suggesting that secondary ASC responses to different antigens from a single vaccine operate independently. In spite of these variable ASC responses, the vaccine efficacy was 100% following challenge for all vaccinees. V. chokerae-specific ASC responses following antigenic reexposure gave information on the presence of mucosal B memory cells but did not correlate with protective immunity. As such, these ASC assays will have limited usefulness for evaluating vaccine responders in vaccine field trials in cholera-endemic areas where prior V. chokerae 01 exposure is unknown.
Specific antibody-secreting cells (ASC) transiently circulate in the peripheral blood after primary oral immunization with live or killed microbial antigens (2, 4, 14) . These cells are believed to originate in the mucosal lymphoid tissue, circulating for a short time before homing back to the mucosa for antibody secretion. They are predominantly of the immunoglobulin A (IgA) class, reflecting their mucosal origin. The detection of these cells after primary stimulation, therefore, reflects priming of the mucosal immune system to locally presented antigens.
Information on the activity of these cells after secondary antigenic stimulation in humans is scant. Recently, it has been shown that secondary oral immunization with live oral Salmonella typhi Ty2la results in an ASC response that is variably present (5, 6) . On the basis of these studies, it has been postulated that vaccines that elicit a more effective local immune response following primary immunization (a process labeled "active immunity") will produce a blunting of a secondary ASC response upon revaccination. The presumed explanation is that B cells primed to produce specific antibody are already in situ and can respond to and contain the antigenic challenge. In addition, it has been postulated that this blunting of the ASC response following secondary antigenic exposure may be indicative of increased mucosal protection (5) .
The recent development and testing of a live attenuated * Corresponding author.
oral Vibrio cholerae 01 vaccine, CVD 103-HgR, offered the unique opportunity to evaluate the ASC response following vaccination and challenge and to test this hypothesis. It has been shown that naturally acquired or experimental infection with V. cholerae induces long-lasting protective immunity associated with gut mucosal IgA antibacterial and antitoxic antibody (9, 13, 18) . A single dose of live attenuated CVD 103-HgR V. cholerae 01 vaccine has been shown to be highly protective in North American volunteer challenge studies conducted within 1 month after vaccination (11, 20 (12) . Diarrhea was defined as 2 or more loose stools in a 48-h period totalling at least 200 ml in volume or a single loose stool 2300 ml. Tetracycline (500 mg every 6 h for 5 days) was given for treatment of diarrhea or prior to discharge for all volunteers.
Immunology. Heparinized blood was drawn before vaccination and on day 4 (for the 8-day challenge study), 7, or 10 after vaccination and challenge. ASC of the IgG, IgM, and IgA classes against V. cholerae 01-specific Inaba lipopolysaccharide (LPS) and CT were measured by ELISPOT as previously described (19 Tables 1 and 2,  respectively. ASC responses following vaccination compared with those of challenged unvaccinated controls. The ASC responses to LPS and CT are presented in Tables 1 and 2 (5, 6) . Secondary challenge with wild-type Shigella sonnei 1 month after primary immunization with 5076-1C, a hybrid vaccine consisting of Ty2la expressing S. sonnei LPS for both S. typhi and S. sonnei, results in a marked increased specific ASC response (21) .
It is probable that the quality of the secondary antigenic stimulation also influences the presence or absence of a secondary ASC response. In our studies, we used a potent secondary antigenic stimulus, namely, a wild-type challenge with an inoculum that leads to a high attack rate in controls. This challenge is clearly different from the booster immunizations with attenuated vaccines used in other studies.
Our data do not support the hypothesis that the absence of a secondary specific ASC response following antigenic rechallenge correlates with protective efficacy. We show that subjects who did not have secondary ASC responses to V. cholerae-specific LPS and CT at 7 or 30 days after vaccination were no less protected than subjects who had marked ASC responses to these antigens upon challenge at 6 months. These antigens were selected because of previous studies suggesting that they are important immunoprotective antigens of V. cholerae (9, 13, 18) . Our conclusions may be limited by the fact that we may not be measuring the ASC responses to all protective antigens of V. cholerae such as surface proteins that mediate virulence through adherence and colonization (3, 15, 17) .
The presence of a specific ASC response after primary immunization also was (16) . In contrast, our data would suggest that the majority of the mucosal antibody response within 6 months after vaccination with CVD 103-HgR is due to memory cells contained within the lamina propria and not to recirculating lymphoblasts.
The magnitude of the secondary ASC response also seems to be antigen specific. For example, the secondary ASC response to V. cholerae LPS was detectable at the 4-month challenge but a CT-specific ASC response was not. The LPS response increased markedly at 6 months. These results suggest that the CT may be a more potent mucosal priming antigen than LPS. The fact that there are variable secondary ASC responses to different antigens in the same vaccine suggest that a reduced secondary ASC response is not simply due to active mucosal immunity reducing bacterial load. If that were the case, specific secondary responses would be the same for all antigens contained in a given vaccine. However, this hypothesis is valid only if antigenic expression of the pathogen is not changed in the immune gut. It is possible that an active mucosal immune response inhibits the production of CT by the invading organisms and thus limits the subsequent specific CT immune response.
The fact that vaccinated volunteers were all uniformly protected against challenge regardless of the time interval before challenge suggests that specific mucosal immunity was not impaired. The uniform protection of vaccinees against challenge also makes it unlikely that suppressor T-cell activity was responsible for the absent secondary ASC response. Detection of a secondary ASC response most likely is dependent on the numbers of specific activated memory B cells present in situ in the lamina propria. The practical implications of these findings are apparent. The primary ASC responses to V. cholerae LPS and CT are of limited value in predicting vaccine efficacy, although they do give vital information on the potency of mucosal priming.
The secondary ASC responses to specific LPS and CT are of even more-limited use in predicting the efficacy of a vaccine, since they are dependent on the strength of the secondary antigenic stimulus and the time interval from primary vaccination. In field conditions, in which the prior exposure history of a given vaccinee is usually unknown, an absent or reduced ASC response following vaccination would be difficult to interpret.
